

Table of Contents

Chapter Number	Details	Page Number
1.0	Introduction	1-19
1.1	Introduction	1
1.1.1	Barriers to effective treatment of cancer	1
1.1.2	Nanoscale carriers as effective cancer treatment vehicles	3
1.1.3	Tumor heterogeneity and use of multiple therapeutic agents in combination	5
1.1.4	Co-delivery of multiple therapeutic agents in combination	6
1.2	Hypothesis	7
1.3	Research Statement	8
1.3.1	Role of Liposomes in cancer combination therapy	8
1.3.2	Conventional Doxorubicin Liposome	10
1.3.3	Conventional vincristine liposome	11
1.3.4	Doxorubicin Vincristine combination and it's benefits:	11
1.4	Aims and objectives of study	13
1.4.1	Aims of the study	13
1.4.2	Objectives of the study	14
1.5	Plan of work	
1.6	References	16
2.0	Literature review	20-115
2.1	Introduction	20
2.2	Current treatment regimens and options	22
2.3	Treatment issues of current therapeutics in NSCLC and TNBC	28
2.3.1	Treatment issues of current therapeutics in NSCLC	28
2.3.2	Treatment issues of current therapeutics in TNBC	31
2.4	Nanocarrier alternatives to conventional therapy	34
2.5	Conventional nanocarriers	36

Chapter Number	Details	Page Number
2.5.1	Passive targeted nanocarriers in NSCLC and TNBC	38
2.5.2	Active targeting nanocarriers in TNBC and NSCLC	45
2.5.3	Ongoing clinical studies of conventional nanocarriers in NSCLC and TNBC	56
2.6	Combinatorial nanocarriers	63
2.6.1	Synergism and MTD for combination therapy	63
2.6.2	Need of combinatorial nanocarriers	63
2.6.3	Dual Drug Combination nanocarriers	65
2.6.4	Drug Gene Combination nanocarriers	72
2.7	Clinical challenges and formulation approaches	76
2.7.1	Preclinical-to-clinical translation	76
2.7.2	Challenges and Opportunities	79
2.7.2.1	Challenges in design and manufacturing	79
2.7.2.2	Opportunities	82
2.8	Conclusion	85
2.9	References	86
3.0	Difference from prior studies of the drug combination in liposomes	116-119
3.1	Dual drug nanocarriers of Doxorubicin and Vincristine	116
3.2	Differences of the proposed study with the earlier reported studies	118
3.3	References	118
4.0	Materials	120-121
4.1	Materials- API and Excipients	120
5.0	Analytical Method development	122
5.1	Introduction	122
5.2	Materials	122
5.3	Method development for simultaneous estimation of Assay of both drugs	123

Chapter Number	Details	Page Number
	5.3.1 Adaptation of USP based assay methods	123
	5.3.2 Change in buffer system and elution technique	125
	5.3.3 Change in pH of buffer system and column	127
	5.3.4 Change in polarity of mobile phase B	130
	5.3.5 Change in gradient elution program and mobile phase composition	132
	5.3.6 Modulation of chromatographic conditions	134
5.4	Method of analysis of assay and free drug	137
	5.4.1 Method of analysis of assay of both drugs from liposomes	137
	5.4.2 Method of analysis of free drug content of both drugs from liposomes	141
5.5	Method of analysis of assay of lipids	145
	5.5.1 Method of analysis of assay of HSPC and Cholesterol	145
	5.5.2 Method of analysis of assay of mpeg-2000-DSPE	147
7.5	References	149
6.0	Determination of Synergism	150-161
	6.1 Introduction	150
	6.1.1 The integrative approach to use of cocktail of drugs	150
	6.1.2 Need for Synergism and Chou Talalay Method	151
	6.1.3 Rationale based selection of combination drugs and synergism	152
	6.2 Materials and Cell lines	153
	6.2.1 Materials	153
	6.2.2 Cell culture	154
	6.3 Methodology	154
	6.4 Results and discussion	155
	6.5 Conclusion	158
	6.6 References	158

Chapter Number	Details	Page Number
7.0	Formulation Development & Optimization	162-214
7.1	Introduction	162
7.2	Material and Methods	165
7.2.1	Materials	165
7.2.2	Liposome Preparation and active drug loading	167
7.2.3	Entrapment efficiency	168
7.2.4	Particle size and zeta potential	169
7.2.5	Cryogenic-transmission electron microscopy (cryo-TEM)	169
7.2.6	Drug release and release kinetics	170
7.2.7	Physical form of DOX in liposomes	170
7.2.8	Factorial Design	171
7.2.9	Statistics	171
7.3	Results and discussion	171
7.3.1	Phosphatidyl Choline chain length	172
7.3.2	Transmembrane salt gradient	178
7.3.3	Drug loading temperature	182
7.3.4	Concentration of cholesterol (lipid molar ratio)	184
7.3.5	Sequence of addition of drugs	186
7.3.6	pH of drug loading	187
7.3.7	External medium	189
7.3.8	Drug to lipid molar ratio	190
7.3.9	Concentration of ammonium sulphate	191
7.3.10	Factorial design	194
7.3.11	Particle size	195
7.3.12	Zeta Potential	198
7.3.13	Entrapment efficiency (EE) and Morphology	199
7.3.14	Drug release and Kinetics	203
7.4	Conclusion	206
7.5	References	207

Chapter Number	Details	Page Number
8.0	Characterization of Optimized formulation	215-266
8.1	Introduction	215
8.2	Materials	216
8.3	Characterization of optimized formulation	217
8.3.1	Preparation of liposomes	217
8.3.2	Quantification of drugs in optimised liposome	218
8.3.3	Quantification of lipids	219
8.3.4	Particle size and Zeta Potential measurements	219
8.3.5	Attenuated total reflection -fourier transform infrared spectroscopy	220
8.3.6	Microcalorimetry	220
8.3.7	Shape, size, morphology and lamellarity using cryo-TEM	221
8.3.8	Morphological evaluation using AFM and FESEM	221
8.3.9	Fixed aqueous layer thickness (FALT) study	222
8.3.10	Electrolyte-induced flocculation/aggregation	222
8.3.11	Interaction with serum proteins and protein adsorption	222
8.3.12	Plasma stability study	223
8.3.13	Liposome membrane integrity test	223
8.3.14	Characterization using small angle x-ray scattering (SAXS)	224
8.3.15	In-vitro drug release study	224
8.3.16	Drug release kinetics study	225
8.3.17	Haemolysis Study	225
8.3.18	Stability Study	226
8.4	Results and Discussion	226
8.4.1	Preparation of liposomes	226
8.4.2	Quantification of drugs and lipids in optimised liposomes	227
8.4.3	Particle size and zeta potential measurements	230

Chapter Number	Details	Page Number
8.4.4	Attenuated Total reflection -Fourier transform infrared spectroscopy	230
8.4.5	Microcalorimetry	234
8.4.6	Shape, size, morphology and lamellarity using cryo-TEM	235
8.4.7	Morphological evaluation using AFM and FESEM	237
8.4.8	Fixed aqueous layer thickness (FALT) study	239
8.4.9	Electrolyte-induced flocculation/aggregation	240
8.4.10	Interaction with serum proteins and protein adsorption	240
8.4.11	Plasma stability study	243
8.4.12	Liposome membrane integrity test	244
8.4.13	Characterization using small angle x-ray scattering (SAXS)	245
8.4.14	In-vitro drug release study	249
8.4.15	Drug release kinetics study	252
8.4.16	Haemolysis Study	255
8.4.17	Stability Study	258
8.5	Conclusion	261
8.6	References	261
9.0	In-vitro cell line studies	267-297
9.1	Introduction	267
9.1.1	A549 cell line	269
9.1.2	MDA MB-231 cell line	269
9.2	Cell lines and materials	269
9.3	Cell culture	270
9.4	Methodology	270
9.4.1	Cellular uptake study by confocal microscopy	270
9.4.2	Cellular uptake studies using flow cytometry	271
9.4.3	Cell viability assay	271

Chapter Number	Details	Page Number
	9.4.4 Cell cycle analysis	272
	9.4.5 Apoptosis study by Annexin V assay	273
	9.4.6 Wound Scratch Study	273
	9.4.7 Statistics	273
9.5	Results and Discussion	274
	9.5.1 Cellular uptake study by confocal microscopy	274
	9.5.2 Cellular uptake studies using flow cytometry	277
	9.5.3 Cell viability assay	280
	9.5.4 Cell cycle analysis	286
	9.5.5 Apoptosis study by Annexin V assay	287
	9.5.6 Wound Scratch Study	291
9.6	Conclusion	292
9.7	References	293
10.0	In-vivo animal studies	298-320
	10.1 Introduction	298
	10.2 Animals	300
	10.3 Ethical Disclosure	300
	10.4 Methodology	300
	10.4.1 Acute toxicity study	300
	10.4.2 In-vivo efficacy	301
	10.4.3 Pharmacokinetics	301
	10.4.4 Tissue Distribution studies	302
	10.4.5 Statistics	302
	10.5 Results and Discussion	302
	10.5.1 Acute toxicity study	302
	10.5.2 In-vivo efficacy	305
	10.5.3 Pharmacokinetics	311
	10.5.4 Tissue Distribution studies	314
10.6	Conclusion	317

Chapter Number	Details	Page Number
10.7	References	317
11.0	Conclusion	321-323
	Annexure	
	Annexure I: Copyright permissions	324-327
	Annexure II: IAEC approval	328
	Annexure III: Publications	329-340
	Annexure IV: Minitab files	341-357